News Medical on MSN

Study offers a practical strategy to enhance effectiveness of immune checkpoint inhibitors

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.
News Medical

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the tumor site for ...

Statins emerge as potential cancer immunotherapy boosters

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.
ascopubs.org

Monitoring PD-L1 expression in cancer-associated macrophage-like cells as predictor of clinical outcomes in metastatic cancer patients treated with PD-L1 immunotherapies.

Effect of fusobacterium nucleatum on NF-κB/HIF-1α/CCL20 pathway and M2 macrophages infiltration in esophageal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data ...

Kazia Therapeutics Limited: Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia ...